{"links":{"feed":"https://www.erudio.com/reports/evolve-1-nct07075016/feed.json","html":"https://www.erudio.com/reports/evolve-1-nct07075016","json":"https://www.erudio.com/reports/evolve-1-nct07075016.json","markdown":"https://www.erudio.com/reports/evolve-1-nct07075016.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"evolve-1-nct07075016"}},"request":"https://www.erudio.com/contact?report=evolve-1-nct07075016"},"offer":{"cited_clinicians":1,"cited_commentary_sources":6,"verified_hcp_statements":27,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":3},"for_sale":false,"one_off_usd":null,"not_for_sale":{"note":"This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it; a later edition that reaches the minimum is for sale at its normal price.","contact":"https://www.erudio.com/contact?report=evolve-1-nct07075016","email":"hello@erudio.com"},"purchase":{"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=evolve-1-nct07075016","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/evolve-1-nct07075016","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 27 verified statements · 2 from 1 confirmed clinician","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":null,"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-21T03:59:14.509094Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":9,"no_commentary_found":1},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Event-free survival (EFS) in patients with newly diagnosed IDH1-mutated AML ineligible for intensive chemotherapy"},{"claim_count":1,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":1,"title":"Secondary endpoints"},{"claim_count":4,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":6,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.interventions","source_count":4,"title":"Safety and tolerability"},{"claim_count":4,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":7,"coverage":"discussed","id":"A1","source_count":2,"title":"Doublet positioning and the missing head-to-head comparison"},{"claim_count":9,"coverage":"discussed","id":"A2","source_count":4,"title":"Earlier triplet evidence and limits of extrapolation"},{"claim_count":4,"coverage":"discussed","id":"A3","source_count":1,"title":"Residual unmet need and conditional hopes for molecularly selected triplets"},{"claim_count":2,"coverage":"discussed","id":"A4","source_count":1,"title":"Local recruitment and anticipated patient benefit"}],"counts":{"beyond_population_findings":4,"beyond_population_statements":14,"cited_clinicians":1,"cited_clinicians_by_role":{"physician":1},"cited_physicians":1,"cited_sources":6,"claims_by_expression_type":{"comparison":1,"experience":1,"interpretation":9,"opinion":6,"primary_context":1,"restatement":8,"unspecified":1},"claims_by_kind":{"source_observation":27},"clinician_statements":2,"evidence_units":10,"findings":6,"organisational_accounts":2,"people_cited":4,"people_identity_verified":3,"people_total":4,"screened_sources":14,"verified_claims":27},"findings_index":[{"cited_clinicians":0,"id":"F1","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":7},"limitations":3,"links":{"context":2,"support":13},"ma_question":true,"named_voices":3,"passages":6,"sources":4,"sources_by_kind":{"commentary":1,"media":3}},"title":"Phase Ib/II triplet: a speaker highlights activity but needs phase III RCTs","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-5d7bdc4f1e06a162c64b"],"clause":"need phase III RCTs","holders":1},"cited_claim_ids":["claim-5c2bb2f5749bd88b1cf3","claim-5d7bdc4f1e06a162c64b","claim-997feb7f2c226b4163ce","claim-48ee8dc536632febab39"],"clinicians":false,"holders":1,"speakers":3,"view":"reading"},"evidence_line":"11 statements from 3 speakers in 4 sources, 3 of them podcasts or videos","holder_line":"1 of the 3 named speakers in this finding holds this view; 1 of them holds its caveat, “need phase III RCTs”"},{"cited_clinicians":0,"id":"F4","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":0,"views":1},"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":0,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"EVOLVE-1 recruitment: what a speaker hopes for in local AML care","title_holders":{"cited_claim_ids":["claim-e97425af01abab32a99d"],"clinicians":false,"holders":0,"speakers":0,"view":"reading"},"evidence_line":"2 statements in 1 source","holder_line":"No named speaker is counted in this finding: its title's view comes from speakers the source does not name"},{"cited_clinicians":0,"id":"F2","population":"beyond","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":3},"limitations":2,"links":{"context":1,"support":8},"ma_question":true,"named_voices":1,"passages":3,"sources":2,"sources_by_kind":{"media":2}},"title":"Older AML on LIT: what speakers say","evidence_line":"7 statements from 1 speaker in 2 sources, all podcasts or videos"},{"cited_clinicians":0,"id":"F3","population":"beyond","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":4,"views":0},"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":2,"passages":4,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"Early-phase triplet safety: what speakers say","evidence_line":"5 statements from 2 speakers in 3 sources, 2 of them podcasts or videos"},{"cited_clinicians":0,"id":"F5","population":"beyond","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"limitations":3,"links":{"context":0,"support":1},"ma_question":true,"named_voices":0,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"IDH-mutated AML triplets: what a speaker highlights in response depth","title_holders":{"cited_claim_ids":["claim-db291c8b796175b376e6"],"clinicians":false,"holders":0,"speakers":0,"view":"reading"},"evidence_line":"1 statement in 1 source","holder_line":"No named speaker is counted in this finding: its title's view comes from speakers the source does not name"},{"cited_clinicians":1,"id":"F6","population":"beyond","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":4},"limitations":2,"links":{"context":0,"support":4},"ma_question":false,"named_voices":2,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"AML triplets: a clinician seeks durability but notes venetoclax's limits","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-4ac799df80c2c4684b73"],"clause":"note venetoclax's limits","holders":1},"cited_claim_ids":["claim-84ced5906957c367e45c"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"4 statements from 2 speakers in 1 source, a podcast or video","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “note venetoclax's limits”"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Speakers welcome early-phase triplet activity; one says randomized confirmation is required"},{"id":"section-2","level":2,"title":"One institutional X account links recruitment with hoped-for patient benefits"},{"id":"section-3","level":2,"title":"Beyond the trial population"},{"id":"section-4","level":3,"title":"One speaker calls the doublet a “new standard of care”; one discussion highlights the evidence gap between doublets"},{"id":"section-5","level":3,"title":"One speaker describes triplet safety favorably but acknowledges not showing the data"},{"id":"section-6","level":3,"title":"One oncology X account relays that triplets are “redefining outcomes” in IDH-mutated AML"},{"id":"section-7","level":3,"title":"Panel speakers frame triplets as an effort to improve outcomes; one says venetoclax “doesn't solve everything”"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, single group, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Event-free survival (EFS) in patients with newly diagnosed IDH1-mutated AML ineligible for intensive chemotherapy"},{"findings":[],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F4","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F4","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-21T03:59:14.509094Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-21T04:10:25Z","record_hash":"9b7a42b1926bb9149ad09a21a9ea6c559e932acf975af72f79f695c9ba42a503","release_hash":"bb638d6d5b162313c6f21ee17a94a2a886aa51c2d6ee0dc774c877672757a701","report_id":"erudio-nct07075016","run_id":"a9fa4142-e9bd-44db-84c1-6f8a83c1a605","schema_version":"5.0","slug":"evolve-1-nct07075016","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Speakers support EVOLVE-1 on the basis of earlier triplet responses, while one speaker requires randomized phase III confirmation. That speaker also regards ivosidenib/azacitidine as standard care, framing the distinction between a rationale for testing venetoclax and evidence for its routine addition. Favorable tolerability impressions do not establish comparable safety, and the sources reviewed for this edition report no randomized benefit or safety outcomes.","examples":[],"meta_description":"14 sources screened · 27 verified statements (2 from clinicians verified by NPI or staff page) from 6 sources · 6 findings. Updated Nov 21, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-21T04:10:25Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":14},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","23 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 28 sources about other trials or topics are not included.","The sources reviewed for this edition do not constitute a representative survey of HCP opinion; discussion that does not name the trial may be missing.","No randomized EVOLVE-1 efficacy or safety outcome is reported in the cited statements. Earlier triplet findings and targeted-doublet results must remain separate from this trial's results.","No full protocol or exact-trial publication was available to independently check schedule descriptions and detailed methods.","No matching venetoclax product label was available to provide additional drug-specific safety context.","Early-phase reports differ in population descriptions, percentages and follow-up detail; their comparability cannot be established, and one MRD denominator and one survival timepoint are unstated.","One speaker in the IACH discussion remains unidentified. Several named commentators' clinical roles are not independently confirmed, and institutional posts and secondhand reports should not be counted as independent clinician opinions.","Post and publication dates identify when statements appeared, not necessarily when enrollment, conference presentations or analyses occurred."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":3,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":6},"count":6,"evidence_window":{"end":"2026-10-16","start":"2025-05-23"},"retrieval_snapshot":"2026-11-21T03:30:16.588189Z","timeline":[{"count":1,"week":"2025-W21"},{"count":1,"week":"2026-W06"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W42"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07075016:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07075016:context","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:1a345e","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:848173","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925914399073612059:80018c26-12f3-4d13-a9c3-35ae9b905ffa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925916202339016927:1888a0b3-ec28-4f85-8950-ee87716c16a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997843561644192211:24e036f4-c9fc-4982-aa2d-60187ad6a146","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997843701910102334:627e8a53-08bd-4b20-b8ff-593a4e1b2f8c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997843760898867345:0eb5d301-d920-4d46-b18c-42e0f0b8e973","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2018688402455945493:3081b95b-a59c-48fc-b2e2-4f26c2ece7a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2042725275063193994:0eccbd98-4de2-4907-be46-a87fb668d89e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061876616557416505:fcdfbfbf-29cd-473b-9b47-6ef597c745a4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065093584483667998:0bbdf3b0-7fc7-46e3-ab65-35a786d1ef73","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065106169639616871:a44215a6-e6ec-4002-bc72-2213a5074878","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:f_utY2Kf8-o","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:iffbNOG1UZo","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":10,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":14},"count":14,"evidence_window":{"end":"2026-10-16","start":"2025-05-23"},"retrieval_snapshot":"2026-11-21T03:30:16.588189Z","timeline":[{"count":2,"week":"2025-W21"},{"count":1,"week":"2025-W45"},{"count":3,"week":"2025-W50"},{"count":1,"week":"2026-W06"},{"count":1,"week":"2026-W15"},{"count":1,"week":"2026-W23"},{"count":2,"week":"2026-W24"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W42"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":5,"publication":0,"registry":0,"regulatory":0,"x_thread":6,"x_video":0,"youtube":16}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: venetoclax 400","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Acute myeloid leukemia","slug":"acute-myeloid-leukemia"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"EVOLVE-1","aliases":["EVOLVE-1","EVOLVE 1","Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy"],"brief_title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","collaborators":["German-Austrian Acute Myeloid Leukemia Study Group","United Kingdom AML Research Network","Gruppo Italiano Malattie EMatologiche dell'Adulto","Swiss Group for Clinical Cancer Research (SAKK)","Danish Acute Leukemia Group","Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias","Nordic AML Group"],"conditions":["Acute Myeloid Leukemia"],"display_condition":"IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy","display_interventions":[["venetoclax"]],"enrollment":{"count":227,"type":"ESTIMATED"},"interventions":[{"name":"Venetoclax 400","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Placebo","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT07075016","official_title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-12","type":"ESTIMATED"},"primary_endpoints":[{"description":"Event-free survival (EFS) in patients with newly diagnosed IDH1-mutated AML ineligible for intensive chemotherapy, measured from the date of randomization to the date of treatment failure, hematologic relapse from CR/CRh or death from any cause, whichever occurs first. Treatment failure is defined as lack of obtaining either CR or CRh by week 24. Patients evaluable for response but not achieving CR or CRh by week 24 will be considered a treatment failure at day 1 post randomization to avoid ambiguities of variable or prolonged periods without response. Patients who die before week 24 without response assessments will also be considered treatment failures at day 1 post randomization. Patients who are alive but not evaluable for response will be censored at day 1 post randomization. Patients who achieved CR or CRh by week 24 and are not known to have morphologic relapse or died will be censored at the date of the last clinical assessment.","measure":"Event-free survival (EFS) in patients with newly diagnosed IDH1-mutated AML ineligible for intensive chemotherapy","timeFrame":"12 months after inclusion of last AML patient"}],"registered_date":{"date":"2025-07-20","type":"ACTUAL"},"registry_last_updated":"2025-08-19","registry_url":"https://clinicaltrials.gov/study/NCT07075016","short_name":"EVOLVE-1","short_name_basis":"canonical_name","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","start_date":{"date":"2025-08-05","type":"ACTUAL"},"study_design":"interventional, randomized, single group, phase3","study_ids":[{"id":"HO173","type":"sponsor_study_id"},{"id":"2024-512753-24","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}